Abstract: The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: This disclosure presents a MITLIF procedure. The procedure uses a single incision on one side and pedicle screws are placed on that side and through the same incision a facet screw is placed on the opposite side using a series of jigs, and, for example, the hole cutter, drill, guide shaft and screw driver described herein.

Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.

Abstract: The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: The present disclosure relates to substituted fused bi- or tri-heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering a substituted fused bi- or tri-heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: In some examples, an electronic device may determine a target time to which the remaining battery charge is to last, such as based on a user input or historical usage of the electronic device. Additionally, the electronic device may determine a current amount of the battery charge remaining, and may determine user activities likely to occur between the present time and the target time. Based at least partially on the amount of the battery charge remaining and the user activities determined to be likely to occur before the target time, the electronic device may apply one or more power management restrictions to one or more resources of the electronic device.

Abstract: A user context generator determines one or both of a location of a user and contextual information for the user. The contextual information is indicative of content of interest to the user. A custom content generator engine generates customized translated content for the user. Generating the customized translated content includes selecting, from translated content stored in a database, based on the one or both of the determined location of the user and the determined contextual information for the user, translated content to be presented to the user. The customized translated content includes a set of phrases in a source language and corresponding translations of phrases, in the set of phrases, from the source language to a target language. The selected translated content is displayed to the user, such that the user is provided with translated content of interest to the user.

Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: In some examples, an electronic device may determine a target time to which the remaining battery charge is to last, such as based on a user input or historical usage of the electronic device. Additionally, the electronic device may determine a current amount of the battery charge remaining, and may determine user activities likely to occur between the present time and the target time. Based at least partially on the amount of the battery charge remaining and the user activities determined to be likely to occur before the target time, the electronic device may apply one or more power management restrictions to one or more resources of the electronic device.

Abstract: The present invention relates to an electrical assembly which has a conformal coating, wherein said conformal coating is obtainable by a method which comprises: (a) plasma polymerization of a compound of formula (I) and a fluorohydrocarbon, wherein the molar ratio of the compound of formula (I) to the fluorohydrocarbon is from 5:95 to 50:50, and deposition of the resulting polymer onto at least one surface of the electrical assembly: wherein: R1 represents C1-C3 alkyl or C2-C3 alkenyl; R2 represents hydrogen, C1-C3 alkyl or C2-C3 alkenyl; R3 represents hydrogen, C1-C3 alkyl or C2-C3 alkenyl; R4 represents hydrogen, C1-C3 alkyl or C2-C3 alkenyl; R5 represents hydrogen, C1-C3 alkyl or C2-C3 alkenyl; and R6 represents hydrogen, C1-C3 alkyl or C2-C3 alkenyl, and (b) plasma polymerization of a compound of formula (I) and deposition of the resulting polymer onto the polymer formed in step (a).

Abstract: A user context generator determines one or both of a location of a user and contextual information for the user. The contextual information is indicative of content of interest to the user. A custom content generator engine generates customized translated content for the user. Generating the customized translated content includes selecting, from translated content stored in a database, based on the one or both of the determined location of the user and the determined contextual information for the user, translated content to be presented to the user. The customized translated content includes a set of phrases in a source language and corresponding translations of phrases, in the set of phrases, from the source language to a target language. The selected translated content is displayed to the user, such that the user is provided with translated content of interest to the user.

Abstract: The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: In some examples, an electronic device may determine a target time to which the remaining battery charge is to last, such as based on a user input or historical usage of the electronic device. Additionally, the electronic device may determine a current amount of the battery charge remaining, and may determine user activities likely to occur between the present time and the target time. Based at least partially on the amount of the battery charge remaining and the user activities determined to be likely to occur before the target time, the electronic device may apply one or more power management restrictions to one or more resources of the electronic device.

Abstract: The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.